AUTOMATED DNA SYNTHESIZER USING TILTED PLATE TECHNOLOGY

采用倾斜板技术的自动化 DNA 合成仪

• 批准号: 6150337
• 负责人: MICHAL LEBL
• 金额: $ 9.9万
• 依托单位: ILLUMINA, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6150337
• 关键词: biomedical automation; biomedical equipment development; centrifugation; high throughput technology; microarray technology; nucleic acid chemical synthesis; oligonucleotides

The subject of this proposal is the design, construction and evaluation of a prototype of a new instrument for the automated, parallel solid-phase synthesis of large arrays of oligonucleotides (768 to 12,288 compounds in one batch), which will be highly beneficial for the drug genotyping, gene sequencing, and other oligonucleotide involving discovery processes. The principal advantage of this instrument, which sets it apart from currently available synthesizers, is a novel technology for the separation of the solid support from reagent and wash solutions by centrifugation. In this instrument, oligonucleotides will be synthesized in the wells of microtiter plates in a centrifuge. The plates are slightly tilted towards the center of centrifugation, thus forming pockets in each well during centrifugation, in which the solid support is collected, while the liquid is expelled from the wells. This process is mechanically simpler and more efficient compared to currently used technologies, thus enabling the manufacture of more robust, flexible, yet less expensive instruments. Produced arrays of oligonucleotides will be utilized for enabling the Illumina technology of self assembled arrays. PROPOSED COMMERCIAL APPLICATIONS: Synthesizers based on the tilted plate technology in semi- or fully automated mode of operation will have an enormous impact on the simplification and acceleration of the parallel solid-phase synthesis of large DNA arrays for genetic and biomedical research. The synthetic technology will enable Illumina's technology, which is expected to capture significant portion of the DNA research and genotyping market. This market is presently estimated at $100 million per annum.

该提案的主题是设计、构建和评估一种新仪器的原型，用于自动化、并行固相合成大阵列寡核苷酸（一批中768至12，288种化合物），这将非常有利于药物基因分型、基因测序和其他涉及发现过程的寡核苷酸。该仪器的主要优点是通过离心将固体支持物与试剂和洗涤溶液分离的新技术，这使其与目前可用的合成仪区分开来。在该仪器中，寡核苷酸将在离心机中的微量滴定板的威尔斯孔中合成。将板稍微向离心中心倾斜，从而在离心过程中在每个孔中形成袋，固体支持物收集在其中，而液体从威尔斯中排出。与目前使用的技术相比，该过程在机械上更简单，更有效，从而能够制造更坚固，更灵活，但更便宜的仪器。生产的寡核苷酸阵列将用于实现自组装阵列的Illumina技术。拟议的商业应用：基于倾斜板技术的半自动或全自动操作模式的合成器将对遗传和生物医学研究中大型DNA阵列的并行固相合成的简化和加速产生巨大影响。合成技术将使Illumina的技术，预计将捕获DNA研究和基因分型市场的重要部分。目前估计这一市场每年为1亿美元。